| Market Capitalization (Millions $) |
122 |
| Shares
Outstanding (Millions) |
12 |
| Employees |
2 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
2 |
| Cash Flow (TTM) (Millions $) |
2 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Emisphere Technologies Inc. is a biopharmaceutical company based in New Jersey, United States. The company specializes in the development of innovative oral drug delivery technologies. Emisphere's proprietary Eligen technology enables the delivery of therapeutic molecules that are typically administered through injections or intravenous routes, via an oral route.
The company's technology enhances the absorption and bioavailability of drugs by encapsulating them in proprietary carriers, allowing them to efficiently pass through the gastrointestinal tract and be absorbed into the bloodstream. This approach eliminates the need for injections, offering a more convenient and less invasive method of drug administration.
Emisphere has partnered with various pharmaceutical companies and research organizations to develop oral formulations for a wide range of therapeutics, including proteins, peptides, and small molecules. These collaborations aim to improve patient compliance, expand therapeutic options, and enhance the efficacy and safety of drugs.
Emisphere Technologies Inc. has an extensive intellectual property portfolio and has received regulatory approvals for several drug products. The company continues to advance its technology platform and collaborates with industry partners to bring novel oral drug delivery solutions to market.
Company Address: 515 E Las Olas Blvd Fort Lauderdale 33301 FL
Company Phone Number: 282-6717 Stock Exchange / Ticker: NASDAQ EMIS
|
